Recently, Wang Liwei's team from the Department of Oncology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Shanghai Cancer Institute (State Key Laboratory of Oncogenes and Related Genes) collaborated with Renji Hospital Stem Cell Research Center researcher Xue Jing's team to pass single-cell sequencing.
Wang Liwei’s team and Xue Jing’s team from the Stem Cell Research Center of Renji Hospital discovered for the first time a new subpopulation of tumor-associated fibroblasts (CAF) with abnormal glucose metabolism levels through single-cell sequencing and related clinical studies.
In this study, the researchers analyzed various cell components in clinical tissue samples of pancreatic cancer through single-cell sequencing technology, and identified a new CAF subgroup (named meCAF)
Experts said that the results of this research are expected to more accurately screen the target population of immunotherapy, improve the efficacy of pancreatic cancer immunotherapy, and provide new targets and ideas for solving pancreatic cancer immunotherapy drug resistance
It is reported that the relevant results of this research have been patented, and clinical verification and transformation will be carried out soon
Related paper information: https://doi.
https://doi.
org/10.
1038/s41421-021-00271-4
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
